Wedbush Maintains Neutral on Abivax, Lowers Price Target to $118
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $140 to $118.
Wedbush analyst David Nierengarten maintains Abivax (NASDAQ:ABVX) with a Neutral and lowers the price target from $140 to $118.